Mesoblast registers $2.5 million of ADS

New York, Nov. 29 - Mesoblast Ltd. registered to offer $2.5 million of American Depositary Shares in an F-6 filing with the Securities and Exchange Commission.

The registration covers a total of 50 millions ADS at a proposed maximum of $0.05 each. One ADS will represent five ordinary shares of Mesoblast.

Based in Melbourne, Australia, Mesoblast is developing therapies for patients with bone and joint diseases, It has acquired the world-wide license to commercialize orthopedic applications of proprietary adult stem cell technology developed by scientists at South Australia's Hanson Institute and Institute of Medical and Veterinary Science.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.